[1]ChemicalandPharmaceuticalBulletin,1996,vol.44,p.709-714
[1]Patent:US2007/100146,2007,A1.Locationinpatent:Page/Pagecolumn3-4
[2]JournalofMedicinalChemistry,2005,vol.48,p.3481-3491
[3]JournalofMedicinalChemistry,2005,vol.48,p.3481-3491
[4]JournalofMedicinalChemistry,2005,vol.48,p.3481-3491
[1]Patent:US2008/194822,2008,A1.Locationinpatent:Page/Pagecolumn2-3
[2]JournalofMedicinalChemistry,2005,vol.48,p.3481-3491
[3]Patent:US2007/135640,2007,A1.Locationinpatent:Page/Pagecolumn4
[4]Patent:US2008/177074,2008,A1.Locationinpatent:Page/Pagecolumn2;4
[5]Patent:US4988815,1991,A
[6]Patent:EP1609792,2005,A1.Locationinpatent:Page/Pagecolumn5
[7]Patent:US2007/135640,2007,A1.Locationinpatent:Page/Pagecolumn3-4
[8]Patent:US2007/135640,2007,A1.Locationinpatent:Page/Pagecolumn4
[9]Patent:US4988815,1991,A
[1]JournalofMedicinalChemistry,2005,vol.48,p.3481-3491
[1]JournalofMedicinalChemistry,2005,vol.48,p.3481-3491
[2]Patent:WO2004/58759,2004,A1.Locationinpatent:Page84
[3]Patent:WO2004/58759,2004,A1.Locationinpatent:Page255
Title: Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.
Title: Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60.
Title: Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46.
Title: Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47.
